Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026

Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026 Continued Growth Underpins First Full Year Net Revenue of US$115M July 09, 2026 20:30 ET | Source: Mesoblast Limited Mesoblast Limited NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil ® (remestemcel-L-rknd) net revenue of US$36 million for the quarter and US$115 million for the full year ended June 30, 2026.

“We are very pleased with the strong uptake of Ryoncil ® since launch, and with revenues that have already exceeded our initial projections,” said Mesoblast Chief Executive Dr. Silviu Itescu.

Dr. Itescu added: “We anticipate continued revenue growth in the coming fiscal year in line with momentum we are seeing across major U.S. pediatric centers. Our capital position is strong, operational activities are well funded through revenue growth, and the new five-year facility has freed up our label extension and blockbuster products for strategic initiatives.”

Ryoncil ® is the first mesenchymal stromal cell (MSC) product approved by the U.S. Food and Drug Administration (FDA) for any indication and is the only FDA-approved product for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD).

The results presented herein are based on management’s preliminary estimates and remain subject to completion of customary year end closing and audit procedures.

About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate mul...